Nathan Pope, Pharm.D., BCACP, FACA has been named The University of Texas at Austin College of Pharmacy’s new assistant dean of experiential education and will succeed Jennifer Ridings-Myhra, M.Ed., R.Ph., who plans to work with Dr. Pope through July and August to assist in the transition. The start date for this new role is effective July 1, 2021.
The University of Texas at Austin College of Pharmacy moved up in several research funding categories, as reported in the newly-released rankings from the American Association of Colleges of Pharmacy (AACP). The college rose to #8 nationally in total research funding during the 2019-2020 fiscal year, compared to #9 in 2018-2019.
Combining mobile health technology, or mHealth, and community outreach to improve the health outcomes of people experiencing homelessness is the target of a new study led by Division of Health Outcomes Associate Professor Leticia Moczygemba, Pharm.D., Ph.D., thanks to a five-year research grant from the U.S. Department of Health and Human Services Agency for Healthcare Research and Quality.
Three researchers from the College of Pharmacy won an award from the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation. Leticia R. Moczygemba, Pharm.D., Ph.D., Carolyn M. Brown, Ph.D. and Michael Johnsrud, Ph.D., R.Ph. were awarded $5,000 from the PhRMA Foundation for their proposal to advance racial and ethnic representation in value assessments.
“H-E-B has been an innovator in community pharmacy practice in Texas. The UT College of Pharmacy has a long history of collaboration with H-E-B, including training the next generation of pharmacists through internships, experiential rotations, and post-graduate residencies,” said Dean Samuel M. Poloyac. “The opening of the new pharmacy on the UT Austin campus is a wonderful opportunity to enhance our partnership. We are excited to work together on this new endeavor.”
Researchers in the lab of Dr. Hugh D.C. Smyth have released promising results of a new method to treat SARS-CoV-2, the coronavirus that causes COVID-19. The antiviral niclosamide, when incorporated with human lysozyme as a carrier molecule, shows potential as an effective COVID-19 treatment when delivered directly to the airways.